MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections
mBio · 2024
DOI: 10.1128/mbio.02540-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Christian Roehrig und 13 weiteren Autor:innen. Beteiligte Einrichtung: Micreos Pharmaceuticals AG, Baar, Zug, Switzerland. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Sepsis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
One of the most pressing challenges of our era is the rising occurrence of bacteria that are resistant to antibiotics. Staphylococci are prominent pathogens in humans, which have developed multiple strategies to evade the effects of antibiotics. Infections caused by these bacteria have resulted in a high burden on the health care system and a significant loss of lives. In this study, we have successfully engineered lytic enzymes that exhibit an extraordinary ability to eradicate staphylococci. Our findings substantiate the importance of meticulous lead candidate selection to identify therapeutically promising peptidoglycan hydrolases with unprecedented activity. Hence, they offer a promising new avenue for treating staphylococcal infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Micreos Pharmaceuticals AG, Baar, Zug, Switzerland.
- Micreos GmbH, Wädenswil, Zurich, Switzerland.
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences (ZHAW), Wädenswil, Zurich, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Christian Roehrig, Markus Huemer, Annelies S Zinkernagel
Zitieren
APA
Roehrig, C., Huemer, M., Lorgé, D., Arn, F., Heinrich, N., Selvakumar, L., Gasser, L., Hauswirth, P., Chang, C. C., Schweizer, T. A., Eichenseher, F., Lehmann, S., Zinkernagel, A. S., & Schmelcher, M. (2024). MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections. mBio. https://doi.org/10.1128/mbio.02540-23
Vancouver
Roehrig C, Huemer M, Lorgé D, Arn F, Heinrich N, Selvakumar L, et al. MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections. mBio. 2024. doi:10.1128/mbio.02540-23
BibTeX
@article{Roehrig2024,
author = {Roehrig, Christian and Huemer, Markus and Lorgé, Dominique and Arn, Fabienne and Heinrich, Nadine and Selvakumar, Lavanja and Gasser, Lynn and Hauswirth, Patrick and Chang, Chun-Chi and Schweizer, Tiziano A and Eichenseher, Fritz and Lehmann, Steffi and Zinkernagel, Annelies S and Schmelcher, Mathias},
title = {MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.02540-23}
}
EUVIMED